Weir EK, (1989) The acute administration of vasodilator s in primary pulmonary hypertension:experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension,

S, (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension,

Christman BW, (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension,

Tuder RM, (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension,

RJ Rubin LJ, (1996) A comparison of continuous intravenous epoprostenol(prostacyclin)with conventional therapy for primary pulmonary hypertension,

DB, Tapson VF,, (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectum of disease a randomized, controlled trial,

G, Barst RJ,, (2002) Continuous subcutaneous infusion of treprostimil in patients with pulmonary arterial hypertension: a doubleblind, randomized, placebo-controlled trial,

Krause W, (1986) Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man,

MM Olschewski H, (2000) A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension,

T Schmehl T, (2001) Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension,

H Simonneau G, (2002) Inhaled iloprost for severe pulmonary hypertension,

Y Yoshioka T, (1997) Orally active prostacyclin analogue in primary pulmonary hypertension,

N Uematsu M, (1999) Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension,

Galie N,, (2002) Effects of beraprost sodium in patients with pulmonary arterial hypertension: a randomized, doubleblind, placebo-controlled trial,

RJ McGoon M, (2003) Beraprost therapy for pulmonary arterial hypertension,

MR, (1998) Endothelin-1: a mediator of pulmonary hypertension?,

A Remuzzi G, (1999) Endothelin antagonists,

SJ Chen YF, (1995) Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats,

NS Warburton RR, (1997) Nonspecific endothelin-receptor antagonist blunts monocrotaline- in-duced pulmonary hypertension in rats,

JM Wellmann SA, (1999) Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function,

Chan MF, (1997) Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist,

RN Simonneau G, (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension:a randomised placebo-controlled study,

Barst RJ, (2004) Sitaxsentan therapy for pulmonary arterial hypertension,

Hanson KA,, (1998) Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message,

Hanson KA, (1998) Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity,

Braner DA, is a pulmonary vasodilator in lambs, Fineman JR

McMahon TJ, Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed,

Clarke WR,, (1994) The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance,

Cohen AH,, (1996) Inhibition of cyclic3？-5？-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats,

Thusu KG, (1995) The cGMP phosphodiesterase inhibitor zaprinast enhances the effect ofnitric oxide,

Ziegler JW,, (1998) Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus,

Ghofrani HA,, (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension,

E Tymchak W, (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension:comparison with inhaled nitric oxide,

JJ Maroo A, (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension,

AM Wessel DL, (1999) Sildenafil ameliorates effects of inhaled nitric oxide withdrawal,

Wilkens H, (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension,

SH Charfield BA, (1990) Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth,

Villamor E, (1997) Chronic intrauterine pulmonary hypertension impairs endothelial nitric oxide synthase in the ovine fetus,

KA Fouty BW, (1999) The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia,

JP Dzau VJ, (1997) Nitric oxide synthase:role in the genesis of vascular disease,

RD Shesely EG, (1998) Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling,

Loscalzo J, (1995) Nitric oxide and its role in the cardiovascular system,

Buechler WA, (1994) Soluble guanylyl cyclase and platelet function,

Radomski MW, (1993) The biological and pharmacological role of nitric oxide in platelet function,

Zapol WM, (1994) Inhaling nitric oxide:a selective pulmonary vasodilator and bronchodilator,

JP, (1992) Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn,

The Neonatal Inhaled Nitric Oxide Study Group, (1997) Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure,